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1 Medical Materials Laboratory, Department of Metallurgical and Materials Engineering, Indian Institute of Technology Madras,
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Nanotechnology has tremendous potential for the management of infectious diseases
caused by multi-drug resistant bacteria, through the development of newer antibacterial
materials and efficient modes of antibiotic delivery. Calcium phosphate (CaP) bioceramics
are commonly used as bone substitutes due to their similarity to bone mineral and are
widely researched upon for the treatment of bone infections associated with bone loss.
CaPs can be used as local antibiotic delivery agents for bone infections and can be
substituted with antibacterial ions in their crystal structure to have a wide spectrum,
sustained antibacterial activity even against drug resistant bacteria. In the present work,
a dual mode antibiotic delivery system with antibacterial ion substituted calcium deficient
hydroxyapatite (CDHA) nanoparticles has been developed. Antibacterial ions such as
zinc, silver, and strontium have been incorporated into CDHA at concentrations of
6, 0.25–0.75, and 2.5–7.5 at. %, respectively. The samples were found to be phase
pure, acicular nanoparticles of length 40–50 nm and width 5–6 nm approximately. The
loading and release profile of doxycycline, a commonly used antibiotic, was studied from
the nanocarriers. The drug release was studied for 5 days and the release profile was
influenced by the ion concentrations. The release of antibacterial ions was studied over a
period of 21 days. The ion substituted CDHA samples were tested for antibacterial efficacy
on Staphylococcus aureus and Escherichia coli by MIC/MBC studies and time-kill assay.
AgCDHA and ZnCDHA showed high antibacterial activity against both bacteria, while
SrCDHA was weakly active against S. aureus. Present study shows that the antibiotic
release can provide the initial high antibacterial activity, and the sustained ion release can
provide a long-term antibacterial activity. Such dual mode antibiotic and antibacterial ion
release offers an efficient and potent way to treat an incumbent drug resistant infection.
Keywords: doxycycline, calcium phosphate bioceramics, antibacterial ion substitutions, bone infections, silver,
zinc, strontium, calcium deficient hydroxyapatite
Introduction
Bone infections are becoming a frequent occurrence due to human longevity, increasing usage of
prosthetic implants, and prevalence of drug resistant bacteria. These antibiotic resistant infections
place immense burden on the health care system due to the medical complications, long duration of
hospitalization, and associated costs. Bone and joint infections mostly fall into three types namely,
osteomyelitis (infection of bones), septic arthritis (infection of joints), and prosthetic joint infections
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(Bejon and Robinson, 2013). Gram-positive bacteria like Staphy-
lococcus aureus, β-hemolytic Streptococci, Enterococci, Coagulase-
negative Staphylococci, Haemophilus influenza, Escherichia coli,
and Enterobacteriaceae are commonly implicated in these infec-
tions (Bejon and Robinson, 2013). Osteomyelitis is caused by
bacteria introduced through trauma, surgery, direct colonization
from a proximal infection, or through systemic circulation. Pros-
thetic joint infections are most often hospital acquired or noso-
comial in origin. Contamination of implant site can occur from
sources like the air of the operating room and resident bacteria on
the patient’s skin and body. Bacterial adhesion on the prosthesis
results in biofilm formation, which renders bacteria resistant to
most first-line antibiotics (Gristina, 1987). It is estimated that
every year more than 2.2 million people are treated surgically for
musculoskeletal disorders (Gentleman and Polak, 2006). Another
study indicates the incidence of bone infections as approximately
5% of surgeries for fracture fixation devices, 2% of primary joint
replacements, and 1.4–4% of total hip and knee replacements
(Verron et al., 2012).
Treatment of bone infection involves systemic (intravenous)
antibiotic administration in acute conditions and surgical excision
of necrosed bone in chronic infections. Systemic administration of
antibiotics suffers from side effects and is influenced by factors like
the dosage interval and duration (Wu and Grainger, 2006). Bone
infections associated with poorly vascularized or necrotic areas
receive fluctuating and inadequate dose not capable of destroying
the bacterial biofilm. Due to these problems, local drug delivery
of antibiotics is favored. The advantages of local delivery include
lowered dose, greater control over drug bioavailability and release
profile, maintenance of therapeutic concentration at the infection
site, avoidance of side effects, and lowered cost (Huh and Kwon,
2011). Currently, the gold standard in local delivery for bone
infections is poly methyl methacrylate (PMMA) containing gen-
tamycin available as beads and cement (McLaren, 2004). Various
other biopolymers have been tried as drug carriers. However,most
polymers are not bioactive, mostly non-biodegradable, and the
degradation products produce inflammatory reactions at the local
site (Madhumathi and Sampath Kumar, 2014). Bone destruction
and defects commonly occur because of bone infections or post
surgery. In such cases, osteoconductive or osteoinductive bioma-
terials promoting bone repair, and regeneration is preferable over
polymers as delivery vehicles of antibiotics.
Bioactive ceramics such as calcium phosphate ceramics (CPCs)
are attractive candidates for local drug delivery. Hydroxyapatite
(HA), calcium deficient hydroxyapatite (CDHA), and tricalcium
phosphate (TCP) are some of the CPCs of interest in bone
therapeutics. Their degradation products are calcium and phos-
phate ions, which are commonly present in the human body
(Bose and Tarafder, 2012). Human bone is considered as a com-
posite of collagen biopolymer (~20%), reinforced with carbon-
ated non-stoichiometric apatite (~70%) nanocrystals (Dorozhkin,
2010). These apatite nanocrystals have plate like morphology
with width 15–30 nm and length 30–50 nm. Among the CPCs,
CDHA [Ca10-x(HPO4)x(PO4)6-x(OH)2-x; Ca/P= 1.33–1.66] with
tailorable Ca/P ratio and degradability is preferred for drug deliv-
ery applications (Victor and Kumar, 2008; Madhumathi and Sam-
pathKumar, 2014). CDHA is structurally similar to stoichiometric
HA (non-biodegradable) and compositionally can be varied even
to that of TCP (rapidly biodegradable) (Victor and Kumar, 2008).
The apatitic structure presents multiple functional groups to
which many biomolecules can bind. Our earlier studies have
shown that CDHA nanoparticles of Ca/P ratio 1.61 exhibit the
maximum uptake and release of drugs like doxycycline and tetra-
cycline (Victor and Kumar, 2008; Madhumathi and Sampath
Kumar, 2014).
Although local drug delivery has more advantages compared
to systemic delivery, the main challenge lies in treating drug
resistant infections. Drug resistance results in reduced efficacy
of antibacterial drugs, increasing the morbidity and mortality.
The 2014 WHO global report on drug resistance projects an
alarming scenario where common infections and minor injuries
can kill humans in the near future (World Health Organization,
2014). Some alternate approaches explored include stimulation
of the body’s natural defense system by delivering biological
molecules like cytokines that stimulate cell-mediated immunity
(Li et al., 2009; Boyce et al., 2012), local delivery of antimicrobial
peptides (Costa et al., 2011) etc., and developing antimicrobial
materials such as antimicrobial polymers (Siedenbiedel and Tiller,
2012), antibacterial nanoparticles (Madhumathi et al., 2010), and
a combination of these approaches (e.g., antibiotics with metallic
nanoparticles) (Gu et al., 2003) to which drug resistant pathogens
are susceptible. Ions such as silver, zinc, and strontium exhibit
antibacterial activity against many bacteria. Their mode of action
against bacteria is shown in Figure 1. Silver exerts its antibacterial
activity by both deactivating themitochondrial enzymes as well as
denaturing the DNA of the bacterium (Rameshbabu et al., 2007).
Strontium ions, in addition to being antibacterial, are known to
up regulate osteoblast proliferation and down regulate osteoclast
formation. The bacteriostatic activity of strontium substituted
CDHA has been related to its highly negative zeta potential
compared to pure CDHA (Ravi et al., 2012). Zinc is not only
antibacterial, it also promotes the proliferation of osteoblastswhile
inhibiting osteoclastic bone resorption. In addition, it also exhibits
anti-inflammatory properties. Zinc ions inhibit bacterial growth
by binding to the bacterial membrane affecting calcium uptake
and changing the membrane fluidity (Venkatasubbu et al., 2011).
Some of the ions can also be toxic to mammalian cells. Hence, the
above antimicrobial ions incorporated CPCs have been studied
FIGURE 1 |Major mechanism of action of ions on Staphylococcus
aureus.
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FIGURE 2 | Schematic illustration of dual mode CDHA nanocarriers
with initial drug release followed by sustained ion release.
for their antibacterial activity and biocompatibility to establish
the therapeutic limit of ion substitution (Rameshbabu et al., 2007;
Venkatasubbu et al., 2011; Ravi et al., 2012). The ion substi-
tuted bioceramics present salient features such as cost effective
preparation, long-term storage, and are amenable to sterilization
(Huh and Kwon, 2011). Using the ion substituted bioceramics
as carrier for antibiotics offers multiple advantages such as rapid
and sustained antibacterial effect, broad-spectrum activity, and in
some cases increased potency of drugs (Venkatasubbu et al., 2011).
In this work, an antibiotic delivery system based on antimi-
crobial ion substituted CDHA nanoparticles with dual mode
activity as graphically represented in Figure 2 was developed.
The antibacterial activity was provided by the antibiotic released
during the initial phase, which is followed by that of the sustained
ion release to contain infections. Ion substituted CDHA of Ca/P
1.61 was prepared by incorporating zinc (Zn2+), silver (Ag+),
and strontium (Sr2+) ions separately at optimal concentrations
for the antibacterial effect. All these ions are substituted at the
calcium sites of apatite in exchange for calcium ions. While Ag+
is substituted for Ca2+ at Ca(I) cation site, the Zn2+ and Sr2+
ions can be substituted at the Ca(II) site. The zinc substitution
was fixed at 6 at. % since, zinc substituted HA was also shown to
exhibit beneficial anti-inflammatory activity at 5% concentration
(Velard et al., 2010). Concentrations more than 6% were avoided
due to concerns of toxicity. Silver substitution in CDHA was
fixed at 0.25–0.75 at. % substitution based on earlier studies,
where silver substituted HAs exhibited both antibacterial activity
and biocompatibility at 0.5% substitution while 1% substitution
showed toxicity (Rameshbabu et al., 2007). Another study has
shown that CDHA was both antibacterial and biocompatible at
5 at. % strontium substitution (Ravi et al., 2012). Hence, the
strontium substitution was varied between 2.5 and 7.5 at. %.
Pure as well as ion substituted CDHAs were synthesized by a
microwave accelerated wet chemical synthesis method, which is
a rapid method to produce highly pure nanoparticles of narrow
size distribution (Siddharthan et al., 2004). Doxycycline is a potent
antibiotic, which also exhibits anti collagenase activity thereby
preventing host mediated tissue destruction (Victor and Kumar,
2008). The effects of ion substitutions on the drug release, antibac-
terial activity, and biocompatibility of CDHA nanoparticles have
been studied and analyzed.
Materials and Methods
Materials
Calcium nitrate [Ca3(NO4)24H2O], diammonium hydrogen
phosphate [(NH4)2HPO4], zinc nitrate hexahydrate
[Zn(NO3)2.6H2O], strontium nitrate [Sr(NO3)2], and ammonia
(30% GR) were purchased from MERCK, India. Silver nitrate
(AgNO3) was purchased from SDFCL, India. All chemicals were
pure and of analytical grade. Doxycycline hyclate was purchased
from Sigma-Aldrich, India.
Synthesis
Pure and ion substitutedCDHAswere prepared as reported earlier
(Rameshbabu et al., 2007; Ravi et al., 2012). CDHA nanoparticles
were synthesized using a microwave accelerated wet chemical
synthesis method using Ca3(NO4)24H2O and (NH4)2HPO4 as
precursor solutions mixed at a Ca/P ratio of 1.61. The pH during
the synthesis was maintained above 10 using ammonia. After
complete mixing, the solution was subjected to irradiation in a
microwave oven (BPL, India) of 800W for about 30min using 60%
of the power. The precipitate was then washed thrice with distilled
water to remove ions such as NH4+ and NO2 3 , oven dried at
100°C, and ground to a fine powder using an agatemortar andpes-
tle. The zinc, silver, and strontium substituted CDHAs were syn-
thesized following the same procedure, with the addition of their
respective solutions such as Zn(NO3)26H2O/AgNO3/Sr(NO3)2
to the precursor solution of Ca3(NO4)24H2O and titrated with
(NH4)2HPO4 to obtain (Ca+X)/P ratio of 1.61 (where X=Zn or
Ag or Sr). The ion substituted CDHAs with 6 at. % zinc, 0.25–0.75
at. % silver, and 2.5–7.5 at. % strontium were coded as listed in
Table 1.
Material Characterization
The nanocarriers were characterized for phase purity and struc-
tural analysis by X-ray powder diffraction method (XRD, Bruker
D8 DISCOVER, USA) using Cu Kα radiation (λ= 1.54Å). The
diffraction patterns were recorded with step size of 0.1°/step and
at a scanning rate of 1 step/s. The functional groups present
in pure CDHA and ion substituted CDHA nanocarriers were
analyzed in the spectral range of 4000–510 cm 1 by Fourier trans-
form infrared spectroscopy (Spectrum Two FT-IR spectrometer,
Perkin-Elmer, USA) in the attenuated internal reflection (ATR)
mode. Transmission electron microscopy was used to identify the
morphology of the CDHA samples. The samples were dispersed
in acetone and sonicated for 15min using an ultrasonic bath (Cit-
izen, India) at frequency of 45 kHz. The dispersions were dropped
on carbon-coated copper grids, dried, and examined with a trans-
mission electron microscope (Philips CM20 TEM, Netherlands)
operated at 120 kV. The particle size analysis and zeta potential
measurements of the pure and ion substituted CDHAs were car-
ried out by dynamic light scattering (DLS) technique (Malvern
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TABLE 1 | List of cell parameters, crystallite size, loading and release profiles for ion substituted CDHAs.
Sample code % ionic
substitution
Cell
parameters (Å)
Cell
volume (Å)3
Average crystallite
size (nm)
Doxycycline loading
percentage (%)
(meanSD)
Doxycycline release
percentage (%)
(meanSD)
a c XRD TEM (meanSD)
CDHA – 9.110 6.80 519 25 (410.6) (50.1) 689 611.0
ZnCDHA 6 9.014 6.72 509 19 (390.7) (40.3) 478 571.2
0.25AgCDHA 0.25 9.190 6.82 524 27 (410.5)60.3) 374 491.6
0.5AgCDHA 0.5 9.195 6.81 527 28 (420.9) (60.4) 303 520.8
0.75AgCDHA 0.75 9.198 6.83 529 29 (440.5) (60.4) 275 550.8
2.5SrCDHA 2.5 9.410 6.80 541 34 (470.5) (60.3) 316 511.1
5SrCDHA 5 9.440 6.82 547 38 (490.4) (60.2) 265 540.7
7.5SrCDHA 7.5 9.460 6.83 549 38 (510.2) (60.2) 216 560.9
Zetasizer Nano ZS-90, UK). One milligram of the samples were
dispersed in 10ml distilled water and sonicated for 15min. One
milliliter of the supernatant was then removed and used for DLS
measurements.
In vitro Loading and Release Studies of
Doxycycline
Loading and release studies of doxycycline from pure CDHA
and ion substituted CDHA were performed as described earlier
(Madhumathi and Sampath Kumar, 2014). About 10mg of the
drug was dispersed in 10ml of phosphate buffer solution (PBS)
of pH 7.4. To this, 10mg of CDHA nanocarriers was added. The
samples were placed in water bath at 37°C for 24 h. After 24 h, 2ml
of supernatantwas removed for estimation of doxycycline concen-
tration at 274 nm using UV-Vis spectrophotometer (Lambda 35,
Perkin-Elmer, USA). The samples were centrifuged and dried at
room temperature for 24 h. The amount of drug loaded onto the
nanocarriers was determined by the following equation:
%Drug loading = Ic   Fc=Ic  100 (1)
where Ic and Fc are initial and final concentration of doxycycline
in PBS. The release study was performed by dispersing 10mg of
doxycycline loaded CDHAnanocarriers in PBS solution of pH 7.4
kept in a constant temperature water bath at 37°C. About 2ml of
supernatant was removed for doxycycline estimation and replaced
by fresh PBS at periodic intervals over a period of 7 days. The drug
release profile was determined by measuring the absorbance val-
ues at different time intervals (Fc) from the initial concentration
(Ic). All the experiments were performed in triplicates.
In vitro Dissolution and Ion Release Studies
The in vitro dissolution studies were carried out in PBS of pH
7.4 kept in a constant temperature water bath and maintained at
37°C over a period of 21 days. Ten milligrams of the samples in
powder form were dispersed in 10ml of PBS at a concentration
of 1mg/ml. The weight loss of the samples, pH variations as
well as the ionic concentration in the supernatant solution, was
regularly monitored. At the end of each experiment, the samples
were filtered, dried at 100°C, and weighed to calculate the per-
centage weight loss. The ion release studies were performed by
removing 2ml of the supernatant from each sample and diluting
with 23ml of distilled water to obtain a total volume of 25ml.
The concentration of the released Zn2+, Ag+, and Sr2+ ions were
determined using an inductively coupled plasma optical emission
spectrometer (ICP-OES) (PerkinElmer Optima 5300 DV, USA).
These studies were carried out in triplicates for 1st, 3rd, 7th, 14th,
and 21st day.
In vitro Antibacterial Studies
Various antibacterial studies such as minimum inhibitory con-
centration (MIC), minimum bactericidal concentration (MBC),
time-kill assays were performed on ion substituted CDHAs
against theE. coli (NCIM2931) and S. aureus (NCIM5021), which
were purchased from the National Chemical Laboratory, Pune,
India. The bacteria were stored in glycerol stock at -20°C and
used after revival as and when required. The stage of bacteria was
determined by plotting a growth curve. They were found to be in
stationary phase for MIC/MBC and bacterial growth inhibition
studies. However, they were in log phase for time kill assay in view
of the longer duration of the bacterial study. Pure CDHAwas used
as the control. All tests were performed in triplicates.
Minimum Inhibitory Concentration
Minimum inhibitory concentration is the lowest concentration
of an antimicrobial agent that inhibited the visible growth of
microorganism after incubation of 24 h. Ion substituted CDHA
nanoparticles were suspended in nutrient broth at concentrations
of 300, 200, 100, 75, 50, 25, 10, and 5mg/ml and ultrasonicated
to ensure optimal dispersion. After 24 h, 10 µl of the inoculum
of each microorganism was added to the nanoparticulate suspen-
sion. The suspension was then incubated at 37°C for 24 h in a
shaking incubator (180 rpm). Nanoparticle-free broths containing
bacterial inoculum were used as negative controls. Resazurin dye
was used to assess the viability of bacteria with presence of blue
color indicating bacterial growth inhibition and a change to red
color indicating viable bacteria. About 10 µl of 0.01% resazurin
solution was added to the suspension and incubated for 2 h. The
MIC of the ion substituted CDHAs was calculated as the lowest
concentration of the nanoparticles that did not permit any visible
growth of bacteria (blue color) during 24 h of incubation.
Minimum Bactericidal Concentration
Minimum bactericidal concentration refers to the lowest concen-
tration of an antibacterial agent required to kill the bacteria. In
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order to determine theMBC, theMIC samples prepared at various
concentrations were plated in nutrient agar plates. The plates were
incubated at 37°C for 24 h. The lowest concentration at which no
bacterial colony was observed was taken as the MBC.
Time-Kill Curve
Pellets of pure and ion substituted CDHA samples were prepared
by uniaxial compaction. About 300mg of the nanoparticulate
powder was weighed and compacted in a bench press at a force
of 15 kN. The time-kill curve of these pellets was plotted by
testing against S. aureus bacteria. The pellets were added to 2ml
of nutrient broth containing 1 108 CFU/ml in a 24-well plate
and incubated at 37°C for 1, 3, 5, and 7 days. Pure CDHA was
used as positive control while the bacteria containing broth
without nanoparticles were used as negative control. After each
incubation period, 100 µl of the broth solution was collected from
the 24-well plate and was serially diluted to calculate the number
of surviving colonies. About 50 µl of the aliquot of the latter
was then added onto a nutrient agar and incubated at 37°C for
1 day for colony formation. The colonies formed were examined
and counted. The time-kill curve was plotted as bacterial colony
reduction (log CFU/ml) with time.
Bacterial Growth Inhibition Study on Drug Loaded
Samples
Drug loaded ion substituted samples (1mg) were added to 9ml
of the nutrient broth. The suspensions were then inoculated with
1ml of S. aureus bacterial cultures and were incubated at 37°C for
24 hwith shaking. The antibacterial efficacy of the drug loaded ion
substituted sampleswas determined from the optical density (OD)
of the cultures at 600 nm. The antimicrobial reduction percentage
was calculated using the following equation
Bacterial reduction% = f1  (sample OD/control OD)g100%:
(2)
In vitro Biocompatibility Studies
The biocompatibility of the drug loaded CDHAnanoparticles was
tested against L6 myoblast cells (NCCS, Pune) by MTT [3-(4,
5-181dimethylthiazole-2-yl)-2, 5-diphenyl tetrazolium bromide]
assay. MTT assay is a colorimetric test based on the selective
ability of viable cells to reduce the tetrazolium component of
MTT into purple colored formazan crystals. The L6 myoblast
cells were grown to confluence with Dulbecco’s modifed eagle’s
medium (DMEM), supplemented with 10% fetal bovine serum
(FBS) and 1% 100 antibiotic-antimycotic liquid, and incubated
at 37°Cwith 5% carbon dioxide in a CO2 incubator (Astec, Japan).
The cells were then trypsinized and the number of cells was
counted with the help of a hemocytometer (Marienfeld, Ger-
many). They were then diluted (104 cells per well) and seeded
in 96-well plates and cultured for 24 h. One milligram of the
CDHA samples was suspended in 1ml of DMEM and incubated
at 37°C for 24 h. The media in the 96-well plates were then
replaced with 100 µl of the supernatant from the CDHA sam-
ples and again incubated for 24 h. About 20 µl of 5mg/ml MTT
was added to each well and incubated for 4 h. The formazan
precipitates were solubilized in dimethyl sulfoxide (DMSO) and
the absorbance was measured at 570 nm using a multimode plate
reader (EnSpire, Perkin-Elmer, Singapore). The percentage of
viable cells was calculated as the percentage relative to the control
(standard polystyrene tissue culture plates) using the following
equation
%Cell viability = (mean OD/control OD) 100: (3)
Statistical Analysis
The values are expressed as mean SD. Statistical analysis was
performed using one and two way ANOVA wherever applicable.
The p-value <0.05 was considered statistically significant.
Results
Material Characterization
The XRD pattern of the CDHA and ion substituted CDHAs was
comparedwith the standardHApattern (JCPDS 09-432) as shown
in Figure 3A. All the samples showed similar diffraction pattern
corresponding to the characteristic peaks of HA. The absence
of peaks other than HA confirms the formation of monophase
CDHAs unaffected by ionic substitutions. The average crystallite
size of the particles (t) was calculated from the broadening of
the peak at 26° corresponding to (0 0 2) reflection using Scher-
rer’s formula [t= 0.9λ/Bcosθ], where λ=wavelength of CuKα
radiation and B= full width at half maximum value (in radians)
of the diffraction peak at 26°(2θ). The cell parameters and cell
volume were calculated from the XRD data using the program
“UnitCell” and are listed in Table 1, along with the crystallite
size of the synthesized powders. It can be seen from Table 1 that
the cell parameters varied with the type and concentration of
substituted ions. Compared to pure CDHAs, the cell parameters
and cell volume for zinc substituted CDHA showed a decrease
while there was an increase in the case of silver and strontium
substitution. The average crystallite size of pureCDHAwas 25 nm.
The crystallite size showed variations on ion substitution with
values ranging from 19 nm for zinc to 27–32 nm in case of sil-
ver and strontium substituted CDHAs. The functional groups
present in the ion substituted CDHAs were identified using FT-
IR spectroscopy. Figure 3B shows the typical FT-IR spectra of
pure and ions substituted CDHAs. All the characteristic vibration
bands of CDHA such as PO3 4 (564, 603, 962, and 1032 cm 1),
structural OH  (633 and 3570 cm 1), and CO2 3 (1403 and
1455 cm 1) were present in all the samples (Siddharthan et al.,
2004). The presence of HPO2 4 at 876 cm 1 confirms that the
samples were CDHAs in nature. The absence of any other new
bands suggests that the ions have been substituted into the crys-
tal structure without the formation of any other intermediate
compounds.
The TEM images (Figure 4) show that the nanoparticles
have a rod or acicular morphology. The particle sizes calculated
from TEM micrographs using Image J software are listed in
Table 1. Pure CDHA showed a size of (41 0.6) (5 0.1) nm
while the zinc substituted CDHA show a decrease in the
size (39 0.7) (4 0.3) nm. Both silver and strontium sub-
stituted CDHAs are larger compared to pure CDHA. In case
of silver substitution, the size increases to a maximum of
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FIGURE 3 | Typical XRD spectra of CDHA and various ion substituted CDHAs (A). Typical FT-IR spectra of pure and ion substituted CDHAs (B).
FIGURE 4 | Typical TEM images of CDHA and ion substituted CDHAs.
(44 0.5) (6 0.4) nm approximately while strontium substi-
tutedCDHAs show an even larger size of (51 0.2) (6 0.2) nm
approximately. The particle size obtained from TEM correlates
with that of XRD crystallite results.
In vitro Drug Loading and Release Studies
The loading and release values of doxycycline from CDHA and
ion substituted CDHAs are listed in Table 1. The loading and
release percentage of doxycycline was found to be lower for all
ion substituted samples compared to pure CDHA. In case of
silver and strontium substituted samples, a decrease in loading
of doxycycline with an increase in the amount of ion substitu-
tion was observed. Pure CDHA showed a doxycycline loading
of 68 9% and 69 5% release. The zinc substituted CDHA
showed a loading of 47 8%, while silver substituted CDHAs
showed between (27 5) and (37 4)%, and strontium substi-
tuted CDHAs showed a loading of (21 6)–(31 6)%. One-way
ANOVA test was used to statistically analyze the samples in trip-
licates and the results were statistically significant with p< 0.05.
FIGURE 5 | Release profile of doxycycline from pure CDHA and ion
substituted CDHAs (n=3; data shown as meanSD; p< 0.05,
one-way ANOVA).
The release percentage of doxycycline as listed inTable 1 indicates
a different trend. A classic two-stage release with an initial burst
release in 6 h followed by sustained release was observed. The
release percentage of doxycycline has been found to decrease for
all the substituted CDHAs. However, an increase in release was
observed with increased ion substitution. The 6% zinc substi-
tuted CDHA, 0.25% silver substituted CDHA, and 2.5% strontium
substituted CDHA samples with maximum loading and higher
amount of total drug release were selected as the best samples for
further particle size analysis, in vitro dissolution, and biological
studies. The samples were coded as ZnCDHA, AgCDHA, and
SrCDHA, respectively. The doxycycline loading percentage and
release profile of these nanocarriers are shown in Table 1 and
Figure 5.
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TABLE 2 | List of particle size and zeta potential of CDHA samples.
Samples Hydrodynamic
diameter (d.nm)
(meanSD)
Zeta potential (mV)
(meanSD)
CDHA 141316  20.70.4
AgCDHA 218112  14.90.3
SrCDHA 131307  14.31.0
ZnCDHA 206821  13.70.3
Particle Size Analysis and Zeta Potential
Measurements
The particle size analysis and zeta potential measurements of
CDHA samples by DLS studies are listed in Table 2.
The hydrodynamic diameter obtained is more than 1000 nm
for all samples. The hydrodynamic diameter of AgCDHA and
ZnCDHA was significantly higher than pure CDHA, while that
of SrCDHAwas the lowest. The negative surface charge of CDHA
is reflected in the zeta potential values as expected. The ion sub-
stituted samples exhibit highly negative zeta potential compared
to pure CDHA (Ravi et al., 2012). The studies were conducted
as triplicates. The one-way ANOVA test results were statistically
significant with p< 0.0001.
In vitro Dissolution and Solubility Studies
The in vitro dissolution of CDHA and ion substituted CDHAs
were measured by the weight loss and pH variation as shown
in Figures 6 and 7, respectively. All the synthesized nanopow-
ders showed weight loss from the first day onward (Figure 6).
Compared to pure CDHA, silver substituted CDHAs show a
reduced weight loss suggesting lower solubility and higher stabil-
ity. Strontium substitution on the other hand appears to increase
the solubility of the CDHAs with more than 90% weight loss in a
21 day period. Although, the ZnCDHA exhibited a greater initial
solubility than CDHA for up to 3 days, they show lower solubility
than CDHA from seventh day onward and the difference becomes
statistically significant by 21st day. The dissolution studies were
analyzed by a two-way ANOVA test. The difference between the
samples was found to be statistically significant with p< 0.0001.
The pH values of the PBS solution in which ion substituted
CDHAs were dispersed have also been found to decrease during
this duration as shown in Figure 7A. There was a slight decrease
in the pH from initial 7.4 to 7.32 for AgCDHA and SrCDHA and
reaches 7.15 for ZnCDHA at the end of 21 days. The ion release
profiles obtained from dissolution studies of the samples are
shown in Figure 7B. Zinc ions were found at higher concentration
followed by strontium and silver ions.
In vitro Antibacterial Studies
The MIC and MBC values of the ion substituted samples are
listed in Table 3. It can be seen that AgCDHA has the lowest
MIC and MBC for both the bacteria even at low substitution.
ZnCDHA showed a MIC of 200 µg/µl against both the bacteria.
However, strontium substituted CDHAs showed very low antibac-
terial activity against S. aureus and no activity upto 300 µg/µl
against E. coli. The MBC values also reflect a similar trend.
The time-kill studies on S. aureus showed a reduction in bacte-
rial growth for ion substituted samples. AgCDHA and ZnCDHA
FIGURE 6 | In vitro solubility studies showing the weight loss of ion
substituted CDHAs in PBS of pH 7.4 at 37°C (n= 3; data shown as
meanSD; p< 0.0001, two-way ANOVA).
showed complete inhibition with absence of colonies on second
day itself (Figure 8A). Two-way ANOVA was performed and a
value of p< 0.0001 was obtained. The antibacterial activity of
doxycycline loaded ion substituted CDHA nanoparticles were
determined by incubating them with bacteria in a liquid broth.
The results are shown in Figure 8B. It can be seen that there is a
decrease in the antibacterial activity of the drug loaded substituted
CDHAs compared to only drug loaded pure CDHA. Doxycycline
loaded AgCDHA, especially, showed lower activity than other
samples at the end of 24 h. The statistical analysis was calculated
by one-way ANOVA with p< 0.05 considered significant.
In vitro Biocompatibility Studies
The biocompatibility of the samples before and after drug loading
was tested by MTT assay and the results are shown in Figure 9.
All samples were found to be biocompatible at a concentration of
1mg/ml, with the cell viability above 80% at the end of 48 h. The
biocompatibility of AgCDHA did not vary between 24 and 48 h
of incubation while ZnCDHA and SrCDHA showed a decrease
in cell viability after 24 h. Doxycycline loaded samples showed
variations in biocompatibility in case of ZnCDHA and SrCDHA
at the end of 24 h. Although, drug loaded AgCDHA did not show
any statistical difference in cell viability, there was a reduction
in cell viability for other drug loaded samples compared to pure
samples at 24 h. At the end of 48 h, the cell viability of drug loaded
samples showed no significant variation compared to that of 24 h
incubation. The statistical analysis was conducted by two-way
ANOVA test for triplicate samples with a significance of p< 0.005.
Discussion
Conventional treatment of bone infections suffer from problems
like emergence of drug resistance and persistence of infections
due to inadequate dose, leading to poor healing of bone that can
be addressed with the help of nanotechnology. A dual strategy
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FIGURE 7 | In vitro solubility studies showing pH fluctuations in PBS of pH 7.4 at 37°C (n=3; data shown as mean; p<0.005; one-way ANOVA) (A).
In vitro dissolution studies of CDHA samples showing ion release in PBS of pH 7.4 at 37°C (n= 3; data shown as mean; p<0.005, one-way ANOVA) (B).
TABLE 3 |MIC and MBC values of various ion substituted CDHAs.
Samples S. aureus E. coli
MIC (μg/μl) MBC (μg/μl) MIC (μg/μl) MBC (μg/μl)
ZnCDHA 200 200 200 300
AgCDHA 20 25 10 20
SrCDHA 200 300 – –
of combining antibiotic release with antibacterial ion release can
act effectively against persistent biofilms and can even prevent
emergence of drug resistance. In this regard, CDHAnanoparticles
offers a good platform for both ion substitution and drug release.
The apatitic structure of CDHA provides multiple sites for ion
substitution as well as drug/protein binding. CDHA also has
higher bioactivity, higher specific surface area, and high efficient
precipitation of bone like apatites compared to other calcium
phosphates (Dorozhkin, 2010).
Highly pure ion substituted CDHA nanoparticles were
obtained by microwave accelerated wet chemical method
as evidenced from XRD, FT-IR, and TEM results. The ion
substitutions have been found to influence structural parameters,
drug loading and release capacity, particle stability, antibacterial
activity, and biocompatibility. The cell volume, lattice parameters,
and crystallite size vary with difference in the ionic radii of the
substituting ions compared to calcium ions. ZnCDHA show a
reduction in the cell parameters and size since Zn2+ ions have
a smaller ionic radii of 0.74Å compared to Ca2+ (0.99Å). The
above parameters have been found to increase in AgCDHAs and
SrCDHAs, since Ag+ (1.28Å) and Sr2+ (1.18Å) ions have higher
ionic radii than Ca2+.
The loading and release of doxycycline is also affected by the
ion substitutions. Doxycycline binds to the Ca2+ site of CDHA
(Victor and Kumar, 2008). A partial substitution of Ca2+ by other
ions has reduced the binding sites for doxycycline as seen from the
lower loading percentage. The loading decreases with increasing
ion substitutions. It can be seen that even small amounts of silver
substitution (<1at. %) show a high impact on doxycycline loading.
The drug release percentage and profile was also affected by ion
substitutions. The release profile shows the burst release of the
drug fromAgCDHA and SrCDHA, suggesting surface adsorption
is the mainmechanism of drug binding. It is surprising to observe
that the biphasic release from ZnCDHA is closer to that of CDHA
despite the relatively higher substitution. Since an optimal drug
binding capacity is expected from the CDHA system, samples
were selected based on the loading and release studies. Thus,
0.25% Ag+ substituted CDHA and 2.5% Sr2+ substituted CDHA
was selected for further studies along with 6% Zn substituted
CDHA.
In vitro dissolution and stability studies are essential to under-
stand the behavior of ion substituted CDHA in physiological
system. Since, the antibacterial activity is not only dependant
on drug release but also on ion release, these studies assume
significance. A 21 day study showed that silver substitution low-
ered the solubility while strontium increased the solubility of
CDHA. Substitutions with zinc showed a lower solubility than
pure CDHA at 21st day. At the end of 21 day period, SrCDHA
sample showed the maximum solubility with more than 90%
weight loss. Strontium substitutions are known to decrease the
crystallinity of CDHA, which can be a factor for the high solubility
(Aina et al., 2012; Ravi et al., 2012). The order of weight loss was
SrCDHA>CDHA>ZnCDHA>AgCDHA. This also correlates
well with the ion release, since zinc and strontium ion concen-
tration in PBS was higher than silver ions during this period.
The pH study was done in a buffer solution where immediate
variationmaynot be visible, while ICP analysis indicates the actual
ion concentrations at a higher resolution. Hence, the trend of pH
values may not correlate with Zn ion concentrations at day 1. The
stability of the nanoparticles in a liquid medium was also investi-
gated. The particle size obtained by TEM and the hydrodynamic
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FIGURE 8 | Time-kill curve showing log reduction against S. aureus for
ion substituted CDHA samples (A) (n=3; data shown as mean;
p< 0.0001, one-way ANOVA). Antibacterial activity of CDHA and ion
substituted CDHA nanoparticles loaded with doxycycline (doxy – doxycycline)
against S. aureus (B) (n= 3; data shown as meanSD; p<0.005, one-way
ANOVA).
FIGURE 9 | Biocompatibility studies of pure and doxycycline loaded
ion substituted CDHA samples (1mg/ml) by MTT assay for 24 and 48h
(WD – with doxycycline) (n=3; data shown as meanSD; p< 0.005,
two-way ANOVA).
diameter obtained byDLSmeasurements do not correlate because
of both anisotropic non-spherical nature as well as aggregation of
the nanoparticles. Since, the particles are intended for local drug
delivery, the aggregation of nanoparticles in aqueous medium
should not pose any problem. The zeta potential values also reflect
the unstable nature of the nanoparticles with values between -13.7
and -20.7mV.
Antibacterial activity of ion substituted CDHAs before and
after drug loading was evaluated by multiple studies including
MIC/MBC determination and time-kill assay. TheMIC andMBC
studies test the bacteriostatic (growth inhibitory) and bactericidal
(killing of bacteria) effects of the samples respectively. Of the
three ions, silver is the most potent antibacterial agent, which is
bactericidal in nature. AgCDHA is highly effective against both S.
aureus and E. coli, as can be seen from the MIC and MBC values.
ZnCDHA shows moderate antibacterial activity against both bac-
teria with similar MIC values. However, theMBC of zinc is higher
for E. coli. This is because gram-positive bacteria like S. aureus are
more susceptible to zinc ions than gram-negative E. coli due to
the difference in the protein constituents of their cell walls (Jain
et al., 2013). SrCDHA showed a weak antibacterial activity against
S. aureus.However, no antimicrobial activity was observed against
E. coli at upto 300 µg/µl. The time-kill assay was used to evaluate
the time dependant antibacterial effect of ion substituted CDHAs
on S. aureus bacterial growth. This assay was found to be ideal to
evaluate the antibacterial action of ions released from substituted
CDHAs in a time dependant manner. Similar studies for zinc
substituted HA have been reported earlier (Thian et al., 2013).
The trend observed in the MIC/MBC studies was also reflected
in time-kill studies, with both AgCDHA and ZnCDHA inhibiting
the bacterial growth, as their concentration (300 µg/µl) was more
than their MBC. SrCDHA showed an incomplete growth reduc-
tion since its MBC was more than 300 µg/µl. The antibacterial
activity of doxycycline loaded ion substituted samples against S.
aureus present interesting results. There is an overall marginal
reduction in the antibacterial activity of doxycycline loaded ion
substituted CDHAs compared to pure CDHA at the end of 24 h.
This can be explained in conjunction with the drug loading. The
initial antibacterial activity is provided by the doxycycline drug,
which is loaded at lower amounts in ion substituted samples.
Silver shows the lowest loading (~31%) and hence its antibacterial
activity is also lower than other samples at 24 h. Thus, though
silver ion is highly antibacterial, it is released only by the time
dependant dissolution of the CDHA nanoparticles during which
the drug released provides the antibacterial activity.
Biocompatibility of ion substituted CDHAs is an important
criteria for its clinical applications. Though the ions were sub-
stituted at concentrations deemed biocompatible, the biocom-
patibility of drug loaded substituted CDHAs had to be eval-
uated using MTT assay. The doxycycline concentration was
approximately 0.18 µg/µl for CDHA, 0.26 µg/µl for ZnCDHA,
0.12 µg/µl for AgCDHA, and 0.15 µg/µl for SrCDHA samples
as calculated from drug release studies at the end of 24 h.
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The doxycycline release reduces the cell viability during first 24 h
for ZnCDHA and SrCDHA while no appreciable difference was
observed for AgCDHA samples with and without drug loading.
However, a statistically significant decrease in cell viability was
observed for ZnCDHA and SrCDHA at the end of 48 h compared
to 24 h. However, all the samples were found to be biocompatible
at the given concentration. The results clearly demonstrate the
advantage of ion substituted CDHAs, as the controlled release
of ions incorporated into CDHAs plays an important role in
improving the biocompatibility.
Among various ion substituted CDHAs, AgCDHA with 0.25%
substitution shows the lowest doxycycline loading. However, it
exhibits the highest antibacterial activity and is also biocompat-
ible. The SrCDHA sample shows low loading of doxycycline and
lowest antibacterial activity but exhibits higher biocompatibility.
Although, the ZnCDHA sample exhibits reasonable drug loading
and satisfactory antibacterial activity, it shows lower cell viability
compared to pure CDHA and other ion substituted samples.
The CDHA and AgCDHA samples exhibit drug release up to
5 days while there was no change in the drug release profile
after first day for SrCDHA and ZnCDHA samples. But both
ZnCDHA and AgCDHA show high antibacterial activity at day 2
in spite of their different drug release profiles. Although, SrCDHA
show maximum drug release by first day, it exhibits antibacte-
rial activity from day 2 onward. A long-term antibacterial and
cytotoxic study may clearly bring out the combined role of ion
substitution and drug release in combating antimicrobial resis-
tance.
Thus, the present work demonstrates that by combining antibi-
otics and antimicrobial ions, a biocompatible, sustained, highly
efficient antibacterial bioceramic system with additional benefi-
cial properties such as anti-inflammatory activity or bone remod-
eling activity can be developed to efficiently contain and treat bone
infections.
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